About Flavia Castelino, MD

Dr. Flavia Castelino is the Director of the Scleroderma Program at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. She is a board-certified physician in the Division of Rheumatology and she specializes in  the treatment of scleroderma and connective tissue disease-associated lung disease.

Her research focuses on the role of lipid mediators in scleroderma fibrosis. Dr. Castelino is a member of the Early Career Investigator Subcommittee of the American College of Rheumatology and the Scleroderma Clinical Trials Consortium. She acts as a reviewer for multiple rheumatology journals including Arthritis and Rheumatology, Arthritis Care and Research and Arthritis Research and Therapy.  She is the recipient of numerous awards including the American College of Rheumatology Physician-Scientist Development Award and the Scleroderma Foundation Walter A. Coyle Memorial Research Award. Recently, she was awarded a National Institute of Health research grant to study the role of a lipid mediator, lysophosphatidic acid in scleroderma fibrosis. 

Clinical Interests:



Rheumatology Associates
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-726-7938

Mass General Waltham-Musculoskeletal Ultrasound
52 Second Avenue
Suite 2600
Waltham, MA 02451-1155
Phone: 781-487-6006
Fax: 781-487-4009

Medical Education

  • MD, SUNY at Syracuse (Upstate) College of Medicine
  • SUNY Upstate Medical University at Syracuse, Office of the Registrar
  • Residency, Northwestern Memorial Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Internal Medicine, American Board of Internal Medicine
  • Rheum/Immunology, Unknown Board
  • Rheumatology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Clinical Studies at the MGH Scleroderma Program 

  • Prospective  Registry In Scleroderma at MGH (PRISM)- Database and bio-repository of patients  with scleroderma seen at the MGH Scleroderma Program.
  • Lysophosphatidic Acid (LPA) as a Biomarker in Scleroderma- Evaluate  whether LPA levels in the blood and skin can help us understand disease  progression in scleroderma.
  • MRI to Evaluate Vascular Abnormalities in Scleroderma- Use  of hand MRI to determine whether vascular (blood vessel) abnormalities are an  early finding in scleroderma.
  • Abatacept Systemic Sclerosis Trial (ASSET, Phase II trial)- Evaluate the treatment of Abatacept in patients with diffuse scleroderma.
  • Prospective Registry in Early Systemic Sclerosis (PRESS)- A  collaborative, multi-center database of patients in the early stages of  scleroderma.
  • Scleroderma Clinical Trials Consortium (SCTC)  Calcinosis Working Group-  A collaborative, multi-center database of patients  with scleroderma and calcinosis.

For further  information, please contact: Ana Fernandes (adfernandes@mgh.harvard.edu, 617-724-2792)


  • View my most recent publications at PubMed

    Selected Publications:

    • Schoenfeld SR, Castelino FV. Evaluation and management approaches for scleroderma lung disease. Ther Adv Resp Dis. 2017 Jun 1.
    • Castelino FV, Bain G, Pace VA, Black KE, George L, Probst CK, Goulet L, Lafyatis R, Tager AM. An Autotaxin-LPA-IL-6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis Rheumatol. 2016 Dec;68(12):2964-2974
    • Castelino FV, Varga J. Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy. Curr Opin Rheum 2014 Nov;26(6):607-14
    • Castelino FV, Varga J. Current Status of Systemic Sclerosis Biomarkers. Expert Rev Clin Immunol, 2013 Nov; 9 (11):1077-90.
    • Castelino FV.  Lipids and Eicosanoids in Fibrosis: Emerging Targets for Therapy.  Curr Op Rheum 2012; 24 (6): 649-655.
    • Castelino FV, Goldberg H, Dellaripa PF. The Impact of Rheumatologic Evaluation in the Management of Patients with Interstitial Lung Disease. Rheumatology 2011 Mar;50(3):489-93.
    • Castelino FV, Seiders J, Bain G, Brooks SF, King C, Swaney J, Lorrain D, Chun J, Luster AD, Tager AM. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis and Rheumatism, 2011. May; 63(5):1405-15.